Brief: AEON Biopharma Announces Termination Of Peter Reynolds As CFO
16/05/2024 22:43
May 16 (Reuters) - Aeon Biopharma Inc AEON.A :
* AEON BIOPHARMA INC - TERMINATION OF PETER REYNOLDS AS
CHIEF
FINANCIAL OFFICER, PRINCIPAL FINANCIAL OFFICER AND PRINCIPAL
ACCOUNTING OFFICER OF CO
* AEON BIOPHARMA INC - APPOINTED MARC FORTH AS PRINCIPAL
FINANCIAL OFFICER, EFFECTIVE AS OF MAY 17, 2024
* AEON BIOPHARMA INC - DELIVERED NOTICE TO PPD, INC. TO
DISCONTINUE COMPANY'S PHASE 2 DOUBLE BLIND STUDY OF ABP-450 IN
TREATMENT OF MIGRAINE
* AEON BIOPHARMA INC - TERMINATION OF MIGRAINE STUDY AND OLE
STUDY
WILL ALLOW COMPANY TO CONSERVE CASH WHILE IT EVALUATES ITS
STRATEGIC OPTIONS
Source text for Eikon: ID:n0001837607-24-000066
Further company coverage: AEON.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Aeon Biopharma
See all newsBrief: Aeon Biopharma Reports bpd Type 2A Meeting With FDA And Shareholder Approval Of The November Transactions
Brief: Aeon Biopharma Announces Execution Of Exchange Agreement With Daewoong
Brief: Aeon Biopharma Announces First Closing Of Pipe Investment And Provides Update On FDA Type 2A Meeting Scheduling
Brief: Aeon Biopharma Announces FDA bpd Type 2A Meeting For Abp-450 On November 19
Brief: Aeon Biopharma Announces CEO Transition